What is the price-to-earnings ratio of EyeGene?
The price-earnings ratio of EyeGene is currently 14.49.
EyeGene P/S 2025
EyeGene P/S
14.49
Ticker
185490.KQ
ISIN
KR7185490000
As of Jan 25, 2025, EyeGene's P/S ratio stood at 14.49, a -52.88% change from the 30.75 P/S ratio recorded in the previous year.
The EyeGene P/S history
EyeGene Aktienanalyse
What does EyeGene do?
EyeGene Inc is a biotech company focused on the discovery, development, and commercialization of treatment options for rare eye diseases. EyeGene ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding EyeGene's P/S Ratio
EyeGene's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing EyeGene's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating EyeGene's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in EyeGene’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about EyeGene stock
How has the price-earnings ratio of EyeGene changed compared to last year?
The price-to-earnings ratio of EyeGene has increased by -52.88% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of EyeGene high compared to other companies?
Yes, the price-to-earnings ratio of EyeGene is high compared to other companies.
How does an increase in the price-earnings ratio of EyeGene affect the company?
An increase in the price-earnings ratio of EyeGene would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of EyeGene affect the company?
A decrease in the price-earnings ratio of EyeGene would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of EyeGene?
Some factors that influence the price-earnings ratio of EyeGene are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does EyeGene pay?
Over the past 12 months, EyeGene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyeGene is expected to pay a dividend of 0 KRW.
What is the dividend yield of EyeGene?
The current dividend yield of EyeGene is .
When does EyeGene pay dividends?
EyeGene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of EyeGene?
EyeGene paid dividends every year for the past 0 years.
What is the dividend of EyeGene?
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
In which sector is EyeGene located?
EyeGene is assigned to the 'Health' sector.
Wann musste ich die Aktien von EyeGene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of EyeGene from 1/25/2025 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 1/25/2025.
When did EyeGene pay the last dividend?
The last dividend was paid out on 1/25/2025.
What was the dividend of EyeGene in the year 2024?
In the year 2024, EyeGene distributed 0 KRW as dividends.
In which currency does EyeGene pay out the dividend?
The dividends of EyeGene are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von EyeGene
Our stock analysis for EyeGene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyeGene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
